Raiffeisen Bank International AG Invests $493,000 in Cabaletta Bio, Inc. (NASDAQ:CABA)

Raiffeisen Bank International AG purchased a new stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 220,000 shares of the company's stock, valued at approximately $493,000. Raiffeisen Bank International AG owned approximately 0.45% of Cabaletta Bio at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CABA. Barclays PLC grew its stake in shares of Cabaletta Bio by 48.2% during the third quarter. Barclays PLC now owns 61,130 shares of the company's stock valued at $288,000 after acquiring an additional 19,891 shares in the last quarter. Avanza Fonder AB purchased a new position in Cabaletta Bio in the fourth quarter valued at about $40,000. SG Americas Securities LLC boosted its holdings in Cabaletta Bio by 23.3% in the fourth quarter. SG Americas Securities LLC now owns 43,259 shares of the company's stock valued at $98,000 after purchasing an additional 8,161 shares during the last quarter. HealthInvest Partners AB increased its holdings in Cabaletta Bio by 46.8% during the 4th quarter. HealthInvest Partners AB now owns 247,454 shares of the company's stock worth $554,000 after purchasing an additional 78,932 shares during the last quarter. Finally, Miller Financial Services LLC purchased a new stake in Cabaletta Bio during the 4th quarter worth approximately $33,000.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CABA. Morgan Stanley decreased their price target on shares of Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a research report on Tuesday, April 1st. HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Cabaletta Bio in a report on Tuesday, April 1st. Guggenheim boosted their target price on shares of Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. Citigroup reduced their price target on shares of Cabaletta Bio from $17.00 to $13.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, UBS Group lowered their price objective on Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Cabaletta Bio currently has an average rating of "Buy" and an average target price of $20.33.

Cabaletta Bio Stock Performance

Shares of NASDAQ CABA traded down $0.04 during midday trading on Friday, hitting $1.74. The company's stock had a trading volume of 352,915 shares, compared to its average volume of 1,547,714. Cabaletta Bio, Inc. has a 1-year low of $0.99 and a 1-year high of $13.50. The firm's fifty day moving average price is $1.37 and its 200-day moving average price is $2.17. The firm has a market cap of $88.09 million, a P/E ratio of -0.81 and a beta of 2.72.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last issued its earnings results on Wednesday, May 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.04). As a group, research analysts predict that Cabaletta Bio, Inc. will post -2.34 earnings per share for the current fiscal year.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.